With the rapid pace of immunologic research, it is more important than ever for readers to understand rational immunodiagnosis, immunoprophylaxis, and immunotherapy. This column is intended to help you ensure proper immunologic drug use in your practice.
ParishH.J.A History of Immunizations.Edinburgh and London: Livingstone; 1965.
2.
StiehmE.R.Intravenous immunoglobulins as therapeutic agents. Ann Intern Med.1987; 107: 367–92.
3.
StiehmE.R.Human gamma globulins as therapeutic agents. Adv Pediatr.1988; 35: 1–72.
4.
HambletonP., CarmanJ.A., MellingJ.Anthrax: The disease in relation to vaccines. Vaccine.1984; 2: 125–32.
5.
StiehmE.R.Standard and special human immune serum globulins as therapeutic agents. Pediatrics.1979; 63: 301–19.
6.
GrabensteinJ.D.ImmunoFacts: Vaccines and Immunologic Drugs. 17th rev. Saint Louis: Facts & Comparisons, Inc.; February 2000.
7.
ThalleyB.S., CarrollS.B.Rattlesnake and scorpion antivenoms from the egg yolks of immunized hens. Biotechnology.1990; 8: 934–8.
8.
DomanC.E.Landmarks and pioneers in the control of diphtheria. Can J Public Health.1973; 64: 317–36.
9.
LévyF.M.A corner of history: The fiftieth anniversary of diphtheria and tetanus immunization. Prevent Med.1975; 4: 226–37.
10.
EnglishP.C.Diphtheria and theories of infectious disease: Centennial appreciation of the critical role of diphtheria in the history of medicine. Pediatrics.1985; 76: 1–9.
11.
HróbjartssonA., GotzscheP.C., GluudC.The controlled clinical trial turns 100 years: Fibiger's trial of serum treatment of diphtheria. BMJ.1998; 317: 1243–5.
12.
EnglishP.C.Therapeutic strategies to combat pneumococcal disease: Repeated failure of physicians to adopt pneumococcal vaccine, 1900–1945. Perspect Biol Med.1987; 30: 170–85.
13.
WatsonD.A., MusherD.M., JacobsonJ.W.A brief history of the pneumococcus in biomedical research: A panoply of scientific discovery. Clin Infect Dis.1993; 17: 913–24.
14.
JanewayC.A.Blood and blood derivatives: A new public health field. Am J Public Health.1946; 36: 1–14.
KaoN.L.How immunoglobulins were named [letter]. Ann Intern Med.1992; 117: 445.
25.
StokesJ.JrNeefe JR. The prevention and attenuation of infectious hepatitis by gamma globulin. JAMA.1945; 127: 144–5.
26.
DwyerJ.M.Thirty years of supplying the missing link: History of gamma globulin therapy for immunodeficient states. Am J Med.1984; 76: 46–52.
27.
McCueJ.P., HeinR.H., TenoldR.Three generations of immunoglobulin G preparations for clinical use. Rev Infect Dis.1986; 8(suppl 4): S374–81.
28.
GoodR.A., LorenzE.Historic aspects of intravenous immunoglobulin therapy. Cancer.1991; 68: 1415–21.
29.
JanewayC.A., MerlerE., RosenF.S.Intravenous gamma globulin: Metabolism of gamma globulin fragments in normal and agammaglobulinemic persons. N Engl J Med.1968; 278: 919–23.
30.
GrabensteinJ.D.The safety and hazards of blood-derived drugs. Am J Health-Syst Pharm.1995; 52: 2448–52.
31.
GrabensteinJ.D.Milestones in immunologic history: Antiquity to 1919. Hosp Pharm.1994; 29: 477–8, 480–3.
32.
BreseeJ.S., MastE.E., ColemanP.J.Hepatitis C virus infection associated with administration of intravenous immune globulin: A cohort study. JAMA.1996; 276: 1563–7.
33.
Centers for Disease Control and Prevention.Outbreak of hepatitis C associated with intravenous immunoglobulin administration—United States, October 1993–June 1994. MMWR.1994; 43: 505–9.
34.
BjoroK., FrolandS.S., YunZ.Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med.1994; 331: 1607–11.
35.
PowerJ.P., LawlorE., DavidsonF.Molecular epidemiology of an outbreak of infection with hepatitis C virus in recipients of anti-D immunoglobulin. Lancet.1995; 345: 1211–13.
36.
MeiselH., ReipA., FaltusB.Transmission of hepatitis C virus to children and husbands by women infected with contaminated anti-D immunoglobulin. Lancet.1995; 345: 1209–11.
37.
SchiffR.I.Transmission of viral infections through intravenous immune globulin. N Engl J Med.1994; 331: 1649–50.
WordellC.J.Use of intravenous immune globulin therapy: An overview. DICP–Ann Pharmacother.1991; 25: 805–17.
41.
American Society of Hospital Pharmacists.ASHP therapeutic guidelines for intravenous immune globulin. Clin Pharm.1992; 11: 117–36.
42.
ThürmannP., HarderS.Criteria for the appropriate drug utilisation of immunoglobulin. Pharmacoeconomics.1996; 9: 417–29.
43.
DurongpisitkulK., GururajV.J., ParkJ.M.The prevention of coronary artery aneurysm in Kawasaki disease: A meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics.1995; 96: 1057–61.
44.
National institute of Child Health and Human Development Intravenous Immunoglobulin Study Group.Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. N Engl J Med.1991; 325: 73–80.
45.
SullivanK.M., KopeckyK.J., JocomJ.Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med.1990; 323: 705–12.
46.
GeorgeJ.N., WoolfS.H., RaskobG.E.Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for The American Society of Hematology. Blood.1996; 88: 3–40.
47.
American Society of Hematology.Diagnosis and treatment of idiopathic thrombocytopenic purpura: Recommendations of the American Society of Hematology. Ann Intern Med.1997; 126: 319–26.
48.
RatkoT.A., BurnettD.A., FoulkeG.E.Recommendations for off-label use of intravenously administered immunoglobulin preparations. JAMA.1995; 273: 1865–70.
49.
DalakasM.Intravenous immune globulin therapy for neurologic diseases. Ann Intern Med.1997; 126: 721–30.
50.
BallowM.Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory diseases. J Allergy Clin Immunol.1997; 100: 151–7.
51.
BlasczykR., WesthoffU., Grosse-WildeH.Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations. Lancet.1993; 341: 789–90.
SekulE.A., CuplerE.J., DalakosM.C.Aseptic meningitis associated with high-dose IV immunoglobulin therapy. Ann Intern Med.1994; 121: 259–62.
54.
ScribnerC.L., KapitR.M., PhillipsE.T.Aseptic meningitis and IV immunoglobulin therapy. Ann Intern Med.1994; 121: 305–6.
55.
Centers for Disease Control and Prevention.Renal insufficiency and failure associated with immune globulin intravenous therapy—United States, 1985-1998. MMWR.1999; 48: 518–21.
56.
American Academy of Pediatrics.Recommended timing of routine measles immunization for children who have recently received immune globulin preparations. Pediatrics.1994; 93: 682–5.
57.
Advisory Committee on Immunization Practices.General recommendations on immunization. MMWR.1994; 43(RR-1): 1–38.
58.
GrabensteinJ.D.Vaccines and antibodies in relation to pregnancy and lactation. Hosp Pharm.1999; 34: 949–52, 955–6,959–60.
59.
VaswaniS.K., HamiltonR.G.Humanized antibodies as potential therapeutic drugs. Ann Allergy Asthma Immunol.1998; 81: 105–19.
60.
DeckerE.L., GouveiaW.A.Managing the shortage of intravenous immune globulin. Am J Health-Syst Pharm.1998; 55: 2090, 2093.
61.
Centers for Disease Control and Prevention.Availability of immune globulin intravenous for treatment of immune deficient patients—United States, 1997–1999. MMWR.1999; 48: 159–62.
